These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L Drugs; 2010; 70(1):41-56. PubMed ID: 20030424 [TBL] [Abstract][Full Text] [Related]
4. Nebivolol: third-generation beta-blockade. de Boer RA; Voors AA; van Veldhuisen DJ Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735 [TBL] [Abstract][Full Text] [Related]
5. The role of the new beta-blockers in treating cardiovascular disease. Weber MA Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195 [TBL] [Abstract][Full Text] [Related]
6. Nebivolol: new therapy update. Sule SS; Frishman W Cardiol Rev; 2006; 14(5):259-64. PubMed ID: 16924166 [TBL] [Abstract][Full Text] [Related]
7. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient. Cockcroft J Vasc Health Risk Manag; 2007; 3(6):909-17. PubMed ID: 18200810 [TBL] [Abstract][Full Text] [Related]
8. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Agabiti Rosei E; Rizzoni D Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213 [TBL] [Abstract][Full Text] [Related]
9. Beta-blockers in the management of hypertension: focus on nebivolol. Wojciechowski D; Papademetriou V Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537 [TBL] [Abstract][Full Text] [Related]
10. [Role of the L-arginine/nitric oxide system in the action of nebivolol]. Brodde OE; Philipp T Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442 [TBL] [Abstract][Full Text] [Related]
11. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD; J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441 [TBL] [Abstract][Full Text] [Related]
12. Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Moen MD; Wagstaff AJ Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772 [TBL] [Abstract][Full Text] [Related]
13. Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Coats AJ Drugs Aging; 2006; 23(2):93-9. PubMed ID: 16536633 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Van Bortel LM; Fici F; Mascagni F Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936 [TBL] [Abstract][Full Text] [Related]
16. Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure. Del Sindaco D; Tinti MD; Monzo L; Pulignano G Clin Interv Aging; 2010 Dec; 5():381-93. PubMed ID: 21152240 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Zanchetti A Blood Press Suppl; 2004 Oct; 1():17-32. PubMed ID: 15587108 [TBL] [Abstract][Full Text] [Related]
18. Nebivolol for the treatment of heart failure. Riva N; Lip GY Expert Opin Investig Drugs; 2011 Dec; 20(12):1733-46. PubMed ID: 21980961 [TBL] [Abstract][Full Text] [Related]
19. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. Münzel T; Gori T J Am Coll Cardiol; 2009 Oct; 54(16):1491-9. PubMed ID: 19815121 [TBL] [Abstract][Full Text] [Related]